Abstract
The reverse transcriptase (RT) sequences of HIV-1 subtype C isolates from Indian patients at failure (according to WHO clinical or immunological criteria) of a first-line treatment including d4T/AZT-3TC-NVP/EFV were compared to those of HIV-1 isolates from naive patients and analyzed for drug resistance mutations (DRMs), which were interpreted according to ANRS and Stanford algorithms. All viruses were of subtype C. We have observed a decrease of the polymorphism at positions 36 and 214 of RT while D121Y, V179I, and Q217E could be new DRMs. Numerous crucial DRMs to NRTIs and NNRTIs could be recorded including TAMs of pathway 1 and K65R. According to both algorithms, the accumulation of DRMs may induce resistance to second-line NRTIs including tenofovir.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alkynes
-
Anti-HIV Agents / therapeutic use*
-
Benzoxazines / therapeutic use
-
Cyclopropanes
-
Drug Resistance, Multiple, Viral / genetics
-
Drug Therapy, Combination
-
HIV Infections / drug therapy*
-
HIV Infections / epidemiology
-
HIV Infections / virology*
-
HIV Reverse Transcriptase / genetics*
-
HIV-1 / drug effects
-
HIV-1 / genetics*
-
Humans
-
India / epidemiology
-
Lamivudine / therapeutic use
-
Molecular Sequence Data
-
Nevirapine / therapeutic use
-
Polymorphism, Single Nucleotide
-
Stavudine / therapeutic use
-
Treatment Failure
-
Zidovudine / therapeutic use
Substances
-
Alkynes
-
Anti-HIV Agents
-
Benzoxazines
-
Cyclopropanes
-
Lamivudine
-
Zidovudine
-
Nevirapine
-
Stavudine
-
reverse transcriptase, Human immunodeficiency virus 1
-
HIV Reverse Transcriptase
-
efavirenz
Associated data
-
GENBANK/GU108151
-
GENBANK/GU108177